Stocks · News reference

Clearmind Medicine Announces First Two Alcohol Use Disorder Patients Enrolled At Hadassah Medical Center In Ongoing CMND-100 Trial

Sep 11, 2026, 12:00 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 12, 2026, 11:56 AMBenzinga News-desk
Clearmind Medicine's Charging Robotics Subsidiary Rolls Out Autonomous Vehicle Charging Platform
Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation
CMND
BenzingaOct 8, 2026, 11:33 AMBenzinga Newsdesk
Clearmind Medicine Publishes Patient Application In Japan For Its Compositions And Methods For Treating Dyskinesia
Clearmind Medicine Inc. (Nasdaq: CMND) (the "Company"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric,
CMND
BenzingaOct 7, 2026, 12:40 PMBenzinga Newsdesk
Clearmind Medicine Says It Submitted Recommendations To FDA On Future Therapeutic Use Of Non-Hallucinogenic Psychedelic Drugs
CMND
BenzingaSep 30, 2026, 8:54 PMBenzinga Newsdesk
Clearmind Medicine Announces 1-For-8 Reverse Share Split, Effective October 5, 2026
CMND